Theoretical considerations on quantitative prediction of drug-drug interactions.
暂无分享,去创建一个
Akihiro Hisaka | Yoshiyuki Ohno | A. Hisaka | Hiroshi Suzuki | Takehito Yamamoto | Takehito Yamamoto | Y. Ohno | H. Suzuki
[1] B. Faller. Artificial membrane assays to assess permeability. , 2008, Current drug metabolism.
[2] J. Kolars,et al. First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.
[3] Magang Shou,et al. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. , 2005, Current opinion in drug discovery & development.
[4] Aleksandra Galetin,et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. , 2007, Current drug metabolism.
[5] Alex Avdeef,et al. The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.
[6] F. Guengerich,et al. Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.
[7] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[8] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[9] J. Dressman,et al. Cytochrome P450-mediated metabolism in the human gut wall. , 2009, The Journal of pharmacy and pharmacology.
[10] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[11] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[12] Amin Rostami-Hodjegan,et al. Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.
[13] Barry Press,et al. Permeability for intestinal absorption: Caco-2 assay and related issues. , 2008, Current drug metabolism.
[14] Christopher J Endres,et al. The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] A. Galetin,et al. Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.
[16] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[17] M. Rowland,et al. Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models , 1983, The Journal of pharmacy and pharmacology.
[18] Chuang Lu,et al. RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB , 2005, Drug Metabolism and Disposition.
[19] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[20] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[21] R. Obach,et al. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[22] L J Lesko,et al. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.
[23] Kiyomi Ito,et al. CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.
[24] H. Yamazaki,et al. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[25] C. Crespi. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .
[26] W. Hayton,et al. Dosage Regimen Adjustments in Renal Impairment , 1973 .
[27] Kaoru Kobayashi,et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.
[28] A. Nafziger,et al. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.
[29] Kiyomi Ito,et al. IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.
[30] R. V. van Breemen,et al. Caco-2 cell permeability assays to measure drug absorption , 2005, Expert opinion on drug metabolism & toxicology.
[31] A. Tsuji. Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[32] Aleksandra Galetin,et al. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.
[33] Kazutaka Higaki,et al. Gastrointestinal transit and drug absorption. , 2000, Biological & pharmaceutical bulletin.
[34] H. Kusuhara,et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.
[35] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[36] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[37] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[38] R. Bergstrand,et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine — and its potential clinical relevance , 2004, European Journal of Clinical Pharmacology.
[39] Ken-Ichi Fujita. FOOD-DRUG INTERACTIONS VIA HUMAN CYTOCHROME P450 3A (CYP3A) , 2004, Drug metabolism and drug interactions.
[40] S. Krähenbühl,et al. Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.
[41] Richard Svensson,et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. , 2006, Pharmacological reports : PR.
[42] Y. Sugiyama,et al. A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling , 2009, Clinical pharmacokinetics.
[43] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[44] Akihiro Hisaka,et al. General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs , 2007, Clinical pharmacokinetics.
[45] Shiew-Mei Huang,et al. Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus , 2001, Pharmaceutical Research.
[46] Namandjé N. Bumpus,et al. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. , 2008, Chemical research in toxicology.
[47] Bertram Pitt,et al. Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.
[48] L. Wienkers,et al. Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.
[49] Akihiro Hisaka,et al. General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information , 2008, Clinical pharmacokinetics.
[50] A. Takagi,et al. [Drug-drug interaction of antifungal drugs]. , 2005, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[51] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[52] M. Fromm,et al. In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions , 2009 .
[53] G. Caldwell,et al. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. , 2001, Current topics in medicinal chemistry.
[54] R. Riley,et al. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[55] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[56] J. Spence,et al. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.
[57] Yuichi Sugiyama,et al. Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[58] M. Kato,et al. Intestinal first-pass metabolism of CYP3A4 substrates. , 2008, Drug metabolism and pharmacokinetics.
[59] Kiyomi Ito,et al. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.
[60] Stephen Fowler,et al. In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions , 2008, The AAPS Journal.
[61] Rodrigues Ad,et al. Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .
[62] Robert J Riley,et al. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[63] Jörg Lippert,et al. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.
[64] H. Okuda,et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[65] A. Y. Lu,et al. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[66] Akihiro Hisaka,et al. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. , 2010, Pharmacology & therapeutics.
[67] Aleksandra Galetin,et al. Prediction of In Vivo Drug-Drug Interactions from In Vitro Data , 2006, Clinical pharmacokinetics.
[68] W. Charman,et al. The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.
[69] R. Schlienger,et al. Potential drug–drug interactions in the medication of medical patients at hospital discharge , 2003, European Journal of Clinical Pharmacology.